DK2293804T3 - Herpes simplex virus (hsv) med modificeret tropisme, anvendelser deraf og fremgangsmåde til fremstilling deraf - Google Patents

Herpes simplex virus (hsv) med modificeret tropisme, anvendelser deraf og fremgangsmåde til fremstilling deraf

Info

Publication number
DK2293804T3
DK2293804T3 DK08789969.6T DK08789969T DK2293804T3 DK 2293804 T3 DK2293804 T3 DK 2293804T3 DK 08789969 T DK08789969 T DK 08789969T DK 2293804 T3 DK2293804 T3 DK 2293804T3
Authority
DK
Denmark
Prior art keywords
hsv
applications
producing
herpes simplex
simplex virus
Prior art date
Application number
DK08789969.6T
Other languages
Danish (da)
English (en)
Inventor
Gabriella Campadelli
Laura Menotti
Original Assignee
Univ Bologna Alma Mater
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bologna Alma Mater filed Critical Univ Bologna Alma Mater
Application granted granted Critical
Publication of DK2293804T3 publication Critical patent/DK2293804T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16633—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK08789969.6T 2008-05-29 2008-05-29 Herpes simplex virus (hsv) med modificeret tropisme, anvendelser deraf og fremgangsmåde til fremstilling deraf DK2293804T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2008/000358 WO2009144755A1 (en) 2008-05-29 2008-05-29 Herpes simplex virus (hsv) with modified tropism, uses and process of preparation thereof

Publications (1)

Publication Number Publication Date
DK2293804T3 true DK2293804T3 (da) 2013-08-26

Family

ID=40032777

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13168599.2T DK2700405T3 (en) 2008-05-29 2008-05-29 Herpes simplex virus (HSV) with modified tropism, its uses and method of preparation
DK08789969.6T DK2293804T3 (da) 2008-05-29 2008-05-29 Herpes simplex virus (hsv) med modificeret tropisme, anvendelser deraf og fremgangsmåde til fremstilling deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK13168599.2T DK2700405T3 (en) 2008-05-29 2008-05-29 Herpes simplex virus (HSV) with modified tropism, its uses and method of preparation

Country Status (11)

Country Link
US (2) US9157071B2 (enExample)
EP (2) EP2700405B1 (enExample)
JP (1) JP5683455B2 (enExample)
AU (1) AU2008357065B2 (enExample)
DK (2) DK2700405T3 (enExample)
ES (2) ES2425489T3 (enExample)
HU (1) HUE037311T2 (enExample)
NO (1) NO2700405T3 (enExample)
PL (2) PL2293804T3 (enExample)
PT (2) PT2700405T (enExample)
WO (1) WO2009144755A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9593347B2 (en) 2010-04-16 2017-03-14 University of Pittsburgh—of the Commonwealth System of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors
EP3184641B1 (en) 2013-10-28 2020-07-08 University of Pittsburgh - Of the Commonwealth System of Higher Education Oncolytic hsv vector
ES2874584T3 (es) * 2015-02-11 2021-11-05 Univ Bologna Alma Mater Studiorum Virus del herpes redirigido con una fusión de glicoproteína H
RU2021114137A (ru) 2016-01-27 2021-05-25 Онкорус, Инк. Онколитические вирусные векторы и их применение
WO2017211941A1 (en) 2016-06-09 2017-12-14 Alma Mater Studiorum Universita Di Bologna Herpesvirus with modified glycoprotein b
HUE053007T2 (hu) * 2016-06-09 2021-06-28 Univ Bologna Alma Mater Studiorum Herpeszvírus módosított D glikoproteinnel
RU2021127872A (ru) 2016-06-30 2021-11-09 Онкорус, Инк. Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
US11612625B2 (en) 2017-07-26 2023-03-28 Oncorus, Inc. Oncolytic viral vectors and uses thereof
US11357847B2 (en) 2017-08-30 2022-06-14 Km Biologics Co., Ltd. Modified HSV gD protein and vaccine containing same
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
AU2019292580A1 (en) * 2018-06-29 2021-02-04 Krystal Biotech, Inc. Compositions and methods for antibody delivery
WO2020112471A1 (en) * 2018-11-28 2020-06-04 The Brigham And Women's Hospital, Inc. New generation regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use
CA3124523A1 (en) * 2019-01-03 2020-07-09 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
JP2023502099A (ja) * 2019-11-18 2023-01-20 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド コドン最適化された新世代の調節可能な融合性腫瘍溶解性単純ヘルペスウイルス１型ウイルスおよび使用方法
WO2021251589A1 (ko) * 2020-06-12 2021-12-16 주식회사 젠셀메드 다중 표적화 재조합 헤르페스 심플렉스 바이러스 및 그 용도
CN112501137B (zh) * 2020-11-11 2023-10-20 深圳先进技术研究院 一种神经环路标记系统
CN113969287B (zh) * 2021-10-22 2024-05-28 中国科学院深圳先进技术研究院 重组单纯疱疹病毒的亲和筛选细胞系及其构建方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
CA2279547A1 (en) 1997-01-31 1998-08-06 University Of Rochester Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
US6080399A (en) 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
ATE400030T1 (de) 2001-02-19 2008-07-15 Merck Patent Gmbh Methode zur identifizierung von t-zellepitopen und deren anwendung zur herstellung von molekülen mit reduzierter immunogenität
EP1390069A1 (en) 2001-05-30 2004-02-25 Cornell Research Foundation, Inc. Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
US20040115688A1 (en) 2002-04-19 2004-06-17 Cheung Irene Y. Detection of gd2 synthase mrna and uses thereof
US20070243170A1 (en) * 2002-10-07 2007-10-18 The University Of Chicago Targeting of Herpes Simplex Virus to Specific Receptors
WO2004033639A2 (en) 2002-10-07 2004-04-22 University Of Chicago Targeting of herpes simplex virus to specific receptors
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
EP2433642B1 (en) 2005-10-21 2016-12-07 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
US20080003202A1 (en) 2006-03-28 2008-01-03 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
EP2423305A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
GB0714578D0 (en) * 2007-07-26 2007-09-05 Crusade Lab Ltd Viruses

Also Published As

Publication number Publication date
ES2667622T3 (es) 2018-05-11
EP2700405B1 (en) 2018-04-04
PT2700405T (pt) 2018-05-02
US9744199B2 (en) 2017-08-29
AU2008357065B2 (en) 2013-07-25
HUE037311T2 (hu) 2018-08-28
AU2008357065A1 (en) 2009-12-03
JP5683455B2 (ja) 2015-03-11
US9157071B2 (en) 2015-10-13
PL2293804T3 (pl) 2014-03-31
PL2700405T3 (pl) 2018-08-31
JP2011522532A (ja) 2011-08-04
DK2700405T3 (en) 2018-05-22
EP2293804B1 (en) 2013-05-22
NO2700405T3 (enExample) 2018-09-01
EP2293804A1 (en) 2011-03-16
WO2009144755A1 (en) 2009-12-03
EP2700405A1 (en) 2014-02-26
US20110318268A1 (en) 2011-12-29
US20160074448A1 (en) 2016-03-17
ES2425489T3 (es) 2013-10-15
PT2293804E (pt) 2013-08-29

Similar Documents

Publication Publication Date Title
DK2293804T3 (da) Herpes simplex virus (hsv) med modificeret tropisme, anvendelser deraf og fremgangsmåde til fremstilling deraf
BRPI0822907A2 (pt) Método implementado por computador, e, meio legível por computador
DK2049672T3 (da) Fremgangsmåde til fremstilling af bioethanol og andre fermenteringsprodukter
BRPI0922312A2 (pt) método, e, meio legível por computador
EP2753355A4 (en) ONCOLYTIC HERPES SIMPLEX VIRUS AND THERAPEUTIC USES THEREOF
DK2631291T3 (da) Nukleinsyremolekyler, der inducerer rna-interferens, og anvendelser deraf
DK2791367T3 (da) Mutante mikroorganismer til syntetisering af colansyre, mannosylerede og/eller fucosylerede oligosaccharider
DK3682905T3 (da) Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
DK2708602T3 (da) Xylanaser, nukleinsyrer der koder for dem og fremgangsmåder til fremstilling og anvendelse af dem
DK2334579T3 (da) System og fremgangsmåde til proppant-overførsel
DK3266367T3 (da) Systemer og fremgangsmåder til billeddannelse ved anvendelse af absorption
DK2240203T3 (da) Alfa5-beta1-antistoffer og deres anvendelser
DK2558579T3 (da) Capping-tilbøjelige rna-polymeraseenzymer og anvendelser deraf
HUE051666T2 (hu) Módosított RSV F fehérjék és alkalmazásuk módszerei
BRPI0921651A2 (pt) Método para produzir adenovírus recombinante, e partículas virais, e, biorreator
BRPI0917120A2 (pt) método, e, meio legível por computador.
EP2268813A4 (en) RNA MOLECULES AND USES THEREOF
DK2475372T4 (da) Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse
DK3439184T3 (da) Binarisering af dqp ved anvendelse af særskilte absolutte værdier og tegn (savs, separate absolute value and sign) i cabac
EP2306823A4 (en) 5-FLUOROCYTOSINE FORMULATIONS AND USES THEREOF
DK2344523T3 (da) Gas-kombinationsvacciner og lægemidler
EP2471808A4 (en) PROTEINS ASSOCIATED WITH GRAIN OR LEAF FORMS OF RICE, FOR THESE ENCODING GENES, AND USES THEREOF
BRPI1016039A2 (pt) processo, e, composição antimascaramento.
FI20070991L (fi) Lasituote, tuotteen käyttö ja valmistusmenetelmä
EP2516629A4 (en) VACCINES AGAINST HERPES SIMPLEX VIRUS